EXEL
Exelixis, Inc.
$55.53
-0.32 (-0.57%)
At close · Jul 6
Market Cap
$14.39B
Shares
251,355,083
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.32B
+7%
FY2026
Net Income
$782.57M
+50.1%
FY2026
Gross Margin
96.39%
-0.1pp
FY2026
Operating Margin
37.59%
+9.7pp
FY2026
Diluted EPS
$2.78
+58%
FY2026
Operating Cash Flow
$884.27M
+26.3%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2017 | FY2015 | FY2013 | FY2014 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.38B | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $987.54M | $967.78M | $853.83M | $452.48M | $37.17M | $191.45M | $25.11M | $47.45M | $31.34M | $289.64M | $185.05M | $151.76M | |
| $84.48M | $83.7M | $76.22M | $72.55M | $57.91M | $52.87M | $36.27M | $33.1M | $26.35M | $15.07M | $3.9M | $6.55M | $2.04M | $0 | $1.12M | $0 | — | — | |
| $2.29B | $2.24B | $2.09B | $1.76B | $1.55B | $1.38B | $951.27M | $934.68M | $827.48M | $437.41M | $33.28M | $184.9M | $23.07M | $47.45M | $30.22M | $289.64M | — | — | |
| — | 96.39% | 96.49% | 96.04% | 96.41% | 96.32% | 96.33% | 96.58% | 96.91% | 96.67% | 89.52% | 96.58% | 91.86% | 100% | 96.43% | 100% | — | — | |
| $812.68M | $825M | $910.41M | $1.04B | $891.81M | $693.72M | $547.85M | $336.96M | $182.26M | $112.17M | $96.35M | $95.97M | $189.1M | $128.88M | $178.76M | $156.84M | $210.68M | $234.7M | |
| $40.9M | — | — | — | — | — | — | — | — | — | — | — | — | $31.84M | — | $33.13M | $33.02M | $34.38M | |
| $521.15M | $518.73M | $492.13M | $542.71M | $459.86M | $401.72M | $293.36M | $228.24M | $206.37M | $159.33M | $57.31M | $116.15M | $50.83M | $31.84M | $50.96M | $33.13M | — | — | |
| — | $29.06M | $28.8M | $25.72M | $20.88M | $13.63M | $9.14M | $8.35M | $4.92M | $1.19M | $1.41M | $1M | $2.39M | $5.51M | $3.15M | $6.82M | $10.54M | $12.6M | |
| — | $20.51M | $33.66M | $0 | $0 | — | — | — | $0 | -$32K | $62.83M | $914K | $7.6M | $53.3M | $1.23M | $52.1M | $32.74M | — | |
| — | — | — | — | — | — | — | $598.31M | $414.97M | $286.57M | $158.59M | $219.58M | $249.57M | $169.89M | $232.07M | $200.1M | $276.44M | $273.67M | |
| $1.44B | $1.45B | $1.56B | $1.66B | $1.41B | $1.15B | $877.48M | $598.31M | $414.97M | — | — | — | — | — | — | — | — | — | |
| $936.67M | $872.19M | $604.62M | $170.89M | $201.48M | $286.67M | $110.06M | $369.47M | $438.86M | $165.91M | -$121.42M | -$28.12M | -$224.46M | -$122.44M | -$200.73M | $89.54M | -$91.4M | -$121.91M | |
| — | 37.59% | 27.88% | 9.34% | 12.51% | 19.98% | 11.14% | 38.18% | 51.4% | 36.67% | -326.65% | -14.69% | -893.86% | -258.03% | -640.54% | 30.91% | -49.39% | -80.33% | |
| — | $901.25M | $633.42M | $196.6M | $222.36M | $300.3M | $119.2M | $377.82M | $443.77M | $167.1M | -$120.02M | -$27.12M | -$222.07M | -$116.92M | -$197.59M | $96.36M | -$80.85M | -$109.31M | |
| — | — | — | — | — | — | — | $0 | $0 | $8.68M | $40.68M | $33.06M | $41.36M | $24.78M | $38.78M | $16.26M | $9.34M | $12.67M | |
| $266K | -$198K | -$133K | $93K | -$197K | -$184K | $912K | $28.64M | $13.24M | -$7.33M | -$40.27M | -$42.1M | -$37.02M | -$22.79M | -$37.56M | -$12.54M | -$1.01M | -$18.94M | |
| $112.98M | — | — | — | — | — | $130.84M | $398.11M | $452.09M | $158.58M | -$161.69M | -$70.22M | -$261.48M | -$147.54M | -$244.86M | $76.99M | -$92.4M | -$140.84M | |
| $169.78M | $158.64M | $160.37M | $49.76M | $52.07M | $63.09M | $19.06M | $77.1M | -$237.98M | $4.35M | $55K | $0 | -$182K | $107K | -$96K | $1.3M | -$72K | -$1.29M | |
| $833.42M | $782.57M | $521.27M | $207.77M | $182.28M | $231.06M | $111.78M | $321.01M | $690.07M | $154.23M | -$161.74M | -$70.22M | -$261.3M | -$145.34M | -$238.19M | $75.7M | -$92.33M | -$135.22M | |
| — | 33.73% | 24.04% | 11.35% | 11.31% | 16.1% | 11.32% | 33.17% | 80.82% | 34.09% | -435.12% | -36.68% | -1040.57% | -306.29% | -760.07% | 26.14% | -49.9% | -89.1% | |
| — | — | — | — | — | — | — | $321.01M | $690.07M | $153.86M | -$161.74M | -$70.22M | — | — | — | — | — | — | |
| $831M | $787.39M | $523.67M | $218.54M | $168.52M | $225.83M | $113.19M | $324.78M | $689.72M | $154.3M | -$161.86M | -$70.41M | -$261.56M | -$145.29M | -$237.95M | $75.55M | -$92.47M | -$135.07M | |
| USD/shares | — | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 | $0.36 | $1.06 | $2.32 | $0.52 | -$0.77 | -$0.28 | — | -$0.92 | -$1.33 | $0.60 | -$0.85 | -$1.26 |
| USD/shares | — | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | -$0.77 | -$0.28 | — | -$0.92 | -$1.33 | $0.58 | -$0.85 | -$1.26 |
| shares | — | 271.57M | 290.03M | 318.15M | 321.53M | 314.88M | 308.27M | 302.58M | 297.89M | 293.59M | 209.23M | 250.53M | 194.3M | 160.14M | 184.06M | 126.02M | 108.52M | 107.07M |
| shares | — | 281.86M | 296.13M | 321.46M | 324.56M | 322.36M | 318M | 315.01M | 312.8M | 312M | 209.23M | 250.53M | 194.3M | 160.14M | 184.06M | 130.48M | 108.52M | 107.07M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: $2.15B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
Compare industry multiplesEV/Revenue
—
EV/EBIT
—
P/E (TTM)
18.95×
Biotechnology median 7.16×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2022-12-30 | 2023-12-29 | 2025-01-03 | 2026-01-02 |
|---|---|---|---|---|
| Reportable Segment | $1,611,062,000 | $1,830,208,000 | $2,168,701,000 | $2,320,126,000 |
By Geography (USD)
| Component | 2018-12-28 | 2020-01-03 | 2021-01-01 | 2021-12-31 | 2022-12-30 | 2023-12-29 | 2025-01-03 | 2026-01-02 |
|---|---|---|---|---|---|---|---|---|
| United States | $632,927,000 | $770,244,000 | $752,890,000 | $1,089,396,000 | $1,413,743,000 | $1,645,749,000 | $1,822,992,000 | $2,140,371,000 |
| Europe | $182,879,000 | $152,771,000 | $151,631,000 | $302,073,000 | $168,592,000 | $144,969,000 | $318,633,000 | $154,165,000 |
| Japan | $38,020,000 | $44,760,000 | $83,017,000 | $43,501,000 | $28,727,000 | $39,490,000 | $27,076,000 | $25,590,000 |
By Product & Service (USD)
| Component | 2018-12-28 | 2020-01-03 | 2021-01-01 | 2021-12-31 | 2022-12-30 | 2023-12-29 | 2025-01-03 | 2026-01-02 |
|---|---|---|---|---|---|---|---|---|
| Product Gross | $738,529,000 | $957,621,000 | $962,591,000 | $1,452,913,000 | $1,951,169,000 | $2,272,533,000 | $2,518,246,000 | $3,011,807,000 |
| Product | $619,279,000 | $759,950,000 | $741,550,000 | $1,077,256,000 | $1,401,243,000 | $1,628,879,000 | $1,809,395,000 | $2,122,804,000 |
| Cabometyx | $599,946,000 | $733,421,000 | $718,687,000 | $1,054,050,000 | $1,375,909,000 | $1,614,942,000 | $1,798,237,000 | $2,113,369,000 |
| License | $200,272,000 | $165,914,000 | $167,295,000 | $249,956,000 | $162,056,000 | $178,635,000 | $349,244,000 | $214,375,000 |
| Collaboration | $234,547,000 | $207,825,000 | $245,988,000 | $357,714,000 | $209,819,000 | $201,329,000 | $359,306,000 | $197,322,000 |
| Cometriq | $19,333,000 | $26,529,000 | $22,863,000 | $23,206,000 | $25,334,000 | $13,937,000 | $11,158,000 | $9,435,000 |
| Service | $34,275,000 | $41,911,000 | $78,693,000 | $107,758,000 | $47,763,000 | $22,694,000 | $10,062,000 | -$17,053,000 |
| Product Sales Discounts and Allowances | -$119,250,000 | -$197,671,000 | -$221,041,000 | -$375,657,000 | -$549,926,000 | -$643,654,000 | -$708,851,000 | -$889,003,000 |
| Collaboration License | $192,188,000 | $161,299,000 | — | — | — | — | — | — |
| Collaboration Other | $2,858,000 | -$3,439,000 | — | — | — | — | — | — |
| Collaboration Research And Development Service | $39,501,000 | $49,965,000 | — | — | — | — | — | — |
Key facts
CIK
939767
CUSIP
30161Q104
13F (30d)
20 filings
19 filers
Visit website
Investor relations